Patient characteristics
. | HGBCL (n = 22) . | BL (n = 46) . |
---|---|---|
Median age (range) | 55 (26-77) | 45 (21-69) |
Gender - males | 15 (68%) | 37 (80%) |
ECOG-PS >1 | 8 (36%) | 18 (39%) |
HIV seropositivity | 9 (41%) | 37 (80%) |
HBV or HCV seropositivity | 4 (18%) | 15 (33%) |
B symptoms | 8 (36%) | 20 (43%) |
IPI ≥2 | 18 (82%) | 38 (83%) |
Burkitt lymphoma IPI score ≥2∗ | NA | 25 (54%) |
High LDH serum level | 18 (82%) | 37 (80%) |
Stage (Ann Arbor) III-IV | 20 (91%) | 40 (87%) |
Extranodal disease | 18 (82%) | 32 (70%) |
CNS involvement† | 1 (4%) | 8 (17%) |
Bone marrow infiltration | 2 (9%) | 11 (24%) |
Bulky disease‡ | 11 (50%) | 22 (48%) |
Single hit (FISH; MYC) | 12 (54%) | 46 (100%) |
Double hit (MYC + BCL2 or BCL6) | 9 (41%) | — |
Triple hit (MYC + BCL2 + BCL6) | 1 (4%) | — |
. | HGBCL (n = 22) . | BL (n = 46) . |
---|---|---|
Median age (range) | 55 (26-77) | 45 (21-69) |
Gender - males | 15 (68%) | 37 (80%) |
ECOG-PS >1 | 8 (36%) | 18 (39%) |
HIV seropositivity | 9 (41%) | 37 (80%) |
HBV or HCV seropositivity | 4 (18%) | 15 (33%) |
B symptoms | 8 (36%) | 20 (43%) |
IPI ≥2 | 18 (82%) | 38 (83%) |
Burkitt lymphoma IPI score ≥2∗ | NA | 25 (54%) |
High LDH serum level | 18 (82%) | 37 (80%) |
Stage (Ann Arbor) III-IV | 20 (91%) | 40 (87%) |
Extranodal disease | 18 (82%) | 32 (70%) |
CNS involvement† | 1 (4%) | 8 (17%) |
Bone marrow infiltration | 2 (9%) | 11 (24%) |
Bulky disease‡ | 11 (50%) | 22 (48%) |
Single hit (FISH; MYC) | 12 (54%) | 46 (100%) |
Double hit (MYC + BCL2 or BCL6) | 9 (41%) | — |
Triple hit (MYC + BCL2 + BCL6) | 1 (4%) | — |
ECOG-PS, ECOG performance status score; NA, not applicable.
Burkitt Lymphoma IPI (BL-IPI) includes age ≥40 years old, ECOG-PS >1, serum LDH >3 times upper limit of normal, and CNS involvement.21
Only patients with meningeal disease were considered, whereas patients with intraparenchymal brain lesions were excluded.
Bulky disease was defined by a lesion with the largest diameter of 10 cm or more.